Regulatory Submission refers to the formal submission of documents, data, and applications to competent authorities as part of the licensing and approval process for medicinal products, medical devices, or clinical trials. The objective of every regulatory submission is to provide authorities with the necessary evidence to assess the safety, efficacy, and quality of a product or to approve a study. Regulatory submissions accompany the entire lifecycle of a medicinal product or medical device—from the initial clinical trial to post-market activities following approval.
Types of Regulatory Submissions
Regulatory submissions can be distinguished by their subject matter and their timing within the development cycle. The main categories are: Clinical Trial Applications (CTA) for the regulatory approval of clinical trials, Marketing Authorisation Applications (MAA) for the licensing of medicinal products, and post-approval submissions for variations, renewals, and Periodic Safety Update Reports (PSUR) after approval.
Other relevant submission types include Scientific Advice Requests, Orphan Drug Designations, Pediatric Investigation Plans (PIP), Investigational Medicinal Product Dossiers (IMPD), and Responses to Questions (LoQ) within the framework of the regulatory review process. Emergency approvals (Conditional Marketing Authorisation), approvals under exceptional circumstances, and extensions of the marketing authorisation scope (line extensions, new indications) are also distinct submission types with specific regulatory requirements. In the world of medical devices, regulatory submissions include the technical documentation for CE marking in accordance with EU-MDR 2017/745 and EU-IVDR 2017/746.
Electronic Submission Formats and Standards
Most regulatory authorities now require electronic submissions in standardized formats. The Electronic Common Technical Document (eCTD) is the internationally recognized format for medicinal product applications in the EU, USA, Japan, Canada, and other ICH member regions. The eCTD structures the data to be submitted into five modules: regional information, quality data, non-clinical study reports, clinical study reports, and summaries.
In the EU, the submission of clinical trial applications has been carried out since 2023 via the Clinical Trials Information System (CTIS), which serves as a central portal for all EU member states. CTIS has completely replaced national submission via EudraCT for new studies. For medical devices, technical documentation is submitted in a structured form to Notified Bodies.
Submission Process and Timelines
The submission process follows a defined sequence: first, all required documents are compiled according to the regulatory submission package and subjected to internal quality control. The completeness of the dossier is checked against regulatory checklists before the formal submission takes place. Upon receipt, the authorities validate the completeness of the application and return an acceptance status.
Regulatory assessment timelines are established by regulation. For centralized MAA procedures at the EMA, the standard period is 210 days (including so-called clock-stops for answering regulatory questions). CTA approvals in CTIS must be completed within 45 days (standard procedure) or 30 days (expedited procedure). Regulatory Affairs teams and CROs accompany the entire process, coordinate the timely response to queries, and ensure that all submissions comply with current regulatory requirements. Coordination with local authorities in member states is of particular importance when decentralized or mutual recognition procedures (DCP, MRP, national submissions) run in parallel or sequentially.
Quality Assurance and Submission Management
Successful regulatory submissions require structured submission management. This includes managing document versions, ensuring consistency between summaries and individual documents, and complying with regulatory format requirements. Regulatory Information Management (RIM) systems such as Veeva Vault, CARA, or internal tracking tools support the management of submissions and associated dossier documents.
Quality deficiencies in a regulatory submission—missing documents, inconsistent information, or formatting errors—can lead to a refusal of filing or time-consuming queries. Careful pre-submission quality control, including an internal review by experienced Regulatory Affairs specialists, significantly reduces the risk of such complications. This also includes checking the metadata in the eCTD structure, consistency checks between modules, and validation by eCTD publishing software prior to final submission. Many authorities also offer pre-submission meetings where open questions regarding the planned dossier can be clarified in advance.
Frequently Asked Questions (FAQ)
What is the difference between a CTA and an MAA?
A Clinical Trial Application (CTA) is the application for approval of a clinical trial submitted to the competent national authority (e.g., BfArM or PEI in Germany) and the ethics committee. A Marketing Authorisation Application (MAA), on the other hand, is the comprehensive application for the licensing of a medicinal product after completion of clinical development. The MAA contains the complete quality, non-clinical, and clinical data and is submitted via the centralized procedure at the EMA or via national procedures.
How long does a regulatory submission take until a decision is reached?
The duration depends heavily on the submission type. CTA approvals in CTIS take 30–45 days. The centralized MAA procedure at the EMA has a statutory period of 210 days (net), but can be extended by several months due to clock-stops. Shortened deadlines exist for expedited procedures (PRIME scheme, accelerated assessment). Post-approval variations are processed within a few weeks to several months, depending on the category (Type IA to II).
What role does a CRO play in regulatory submissions?
Full-service CROs like mediconomics undertake the preparation, compilation, and submission of regulatory dossiers on behalf of the sponsor. This includes the creation of the Clinical Study Report (CSR), coordination of the eCTD structure, submission in CTIS, and responding to regulatory queries. Regulatory Affairs experts at the CRO also support the sponsor in strategic planning of the submission pathway and in scientific advice meetings.